TRPV2 and esophageal squamous cell carcinoma: An interesting report showed that TRPV2 is involved in the maintenance of cancer stem cells (CSCs) from ESCC and that tranilast, a TRPV2-specific inhibitor, decreased the population of CSCs, and is a possible candidate drug for combination therapy of ESCC [43].